Michael Stabin

Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma

Gregory A. Wiseman, Christine A. White, Michael Stabin et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2000 · 234 citations

Lymphoid Neoplasia, Radioimmunotherapy Dosimetry Results, Phase I/ii 90 +7

Samarium-153-EDTMP biodistribution and dosimetry estimation.

Janet F. Eary, Conor D. Collins, Michael Stabin et al. · PubMed · 1993 · 226 citations

Osteoporosis, Radiation Medicine, Oncology +17

166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.

Hazel B. Breitz, Richard E. Wendt, Michael Stabin et al. · PubMed · 2006 · 59 citations

High-Dose Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan: Comparative Dosimetric Study for Tailored Treatment

Marta Cremonesi, Mahila Ferrari, Chiara Maria Grana et al. · Journal of Nuclear Medicine · 2007 · 54 citations · Full text

Whole-body biodistribution, radiation absorbed dose and brain SPECT imaging with iodine-123-beta-CIT in healthy human subjects.

John Seibyl, Elizabeth A. Wallace, E. O. Smith et al. · PubMed · 1994 · 50 citations